Samsung Biologics acquires $280m GSK plant, securing first US manufacturing base

Samsung Biologics said Monday it has inked a $280 million agreement to acquire GSK’s biopharmaceutical manufacturing plant in Rockville, Maryland, securing the Korean contract development and manufacturing organization leader its first production site in the United States. According to Samsung Biologics, its wholly owned US subsidiary Samsung Biologics America will acquire 100 percent of Human Genome Sciences. The purchase includes two Current Good Manufacturing Practice, or cGMP, manufacturing